Generation of Haematopoietic Stem Cell Lines Bearing Altered Retinoic Acid Receptors: Study of Differentiation
Generation of Haematopoietic Stem Cell Lines Bearing Altered Retinoic Acid Receptors: Study of Differentiation
Full description
Introduction/Background
Retinoic acid (RA), the natural acidic derivative of vitamin A (retinol), is a critical molecule regulating growth and differentiation of a wide variety of cells. RA is thought to be centrally involved in epithelial differentiation, plays a critical role as a tissue-specific morphogen during embryogenesis and as a suppressor of malignant transformation of epithelial cells both in vitro and in vivo. These diverse and complex biologic effects of RA are mediated through a number of closely related nuclear RA receptors (RARs) that are members of the steroid/thyroid hormone receptor superfamily and possess discrete DNA-binding and RA (ligand) binding domains.
Aims/Hypothesis
Several lines of indirect evidence suggest that RA and RA receptors may be involved in regulating the development of haematopoietic progenitors.
Research
Immortalised haematopoietic stem cell lines containing altered retinoic acid receptors and methods for establishing such lines are available. The cell lines of this invention are either a lympho-haematopoietic stem cell line (EML C1) or a neutrophil progenitor cell line (MPRO). The lympho-haematopoietic cell lines of this invention are continuous SCF-dependent cell lines capable of differentiating into erythroid, myeloid and B lymphocytic lineages. The neutrophil progenitor cell lines are GM-CSF-dependent cell lines capable of differentiating into neutrophils but not into monocytes, mast cells or basophils.
Conclusion
This invention relates to genetic engineering and particularly to haematopoietic cell lines bearing altered retinoic acid receptors.
Relevance/Opportunity
These stem cell lines can be used for the study of differentiation or for screening for and cloning of genes involved in differentiation. Please enquire quoting reference no. TID 00121 regarding licensing or codevelopment partnerships.
Development status
Preclinical
Patent information
US Patent 5,830,760 has been issued.
Related reports
Nov 2010 - 7 pages - $500
Nov 2011 - 61 pages - $3,800
Mar 2008 - 250 pages - $3,995
Mar 2006 - 207 pages - $2,875
May 2011 - 15 pages - $125
May 2011 - 15 pages - $250
Dec 2010 - 37 pages - $500
Sep 2010 - 25 pages - $125
Oct 2011 - 102 pages - $500
Jun 2011 - 39 pages - $500